MS-related healthcare resource use before and during fampridine treatment. Description of data: The additional file includes an overview of the MS-related healthcare resource use in the pre- and post-index period in a tabular format. (DOCX 17 kb
SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documen...
Overview of the characteristics of included studies (utilization of disease prevention). (DOCX 28 kb
Definitions of serious outcomes on individual case reports in VigiBase. (PDF 143Â kb
Abstract Background Multiple sclerosis (MS) patients often suffer from gait impairment and fampridin...
Real-world evidence in multiple sclerosis (MS) is limited by the availability of data elements in in...
Detailed search and data preparation methods. This file includes search strings, grey literature sea...
Overview of the characteristics of included studies (utilization of therapists and counselling servi...
Patient perception of glatiramer acetate treatment efficacy by geographic region. aP < .0001 for Lat...
Adherence, satisfaction and functional health status among patients with multiple sclerosis using th...
Computation of upper risk limits for serious adverse effects based on individual case reports in Vig...
Table S1. Clinical and demographic data of the MS patients and non-neurological disease controls (PD...
Overview of the characteristics of included studies (utilization of outpatient care (physicians), in...
Table S2. Neuroinflammatory and neurodegenerative markers with respect to separation of patients wit...
Table S2. “Overview of medical imaging procedures and cost calculation per SOI”: this file contains ...
Details of Study Methods for 3 Cohort Studies (Diabetes, Dementia, and Stroke). (DOCX 35 kb
SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documen...
Overview of the characteristics of included studies (utilization of disease prevention). (DOCX 28 kb
Definitions of serious outcomes on individual case reports in VigiBase. (PDF 143Â kb
Abstract Background Multiple sclerosis (MS) patients often suffer from gait impairment and fampridin...
Real-world evidence in multiple sclerosis (MS) is limited by the availability of data elements in in...
Detailed search and data preparation methods. This file includes search strings, grey literature sea...
Overview of the characteristics of included studies (utilization of therapists and counselling servi...
Patient perception of glatiramer acetate treatment efficacy by geographic region. aP < .0001 for Lat...
Adherence, satisfaction and functional health status among patients with multiple sclerosis using th...
Computation of upper risk limits for serious adverse effects based on individual case reports in Vig...
Table S1. Clinical and demographic data of the MS patients and non-neurological disease controls (PD...
Overview of the characteristics of included studies (utilization of outpatient care (physicians), in...
Table S2. Neuroinflammatory and neurodegenerative markers with respect to separation of patients wit...
Table S2. “Overview of medical imaging procedures and cost calculation per SOI”: this file contains ...
Details of Study Methods for 3 Cohort Studies (Diabetes, Dementia, and Stroke). (DOCX 35 kb
SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documen...
Overview of the characteristics of included studies (utilization of disease prevention). (DOCX 28 kb
Definitions of serious outcomes on individual case reports in VigiBase. (PDF 143Â kb